Kenya’s Health Ministry clears Lenacapavir to tackle pill fatigue for HIV patients

KENYA—The Ministry of Health in Kenya has taken a significant step forward in HIV prevention by recommending the registration of Lenacapavir, a revolutionary long-acting antiretroviral medicine.

The Pharmacy and Poisons Board has approved both the 300 mg tablet and 464 mg injectable solution forms of the drug for use as pre-exposure prophylaxis (PrEP).

This development arrives just one week after Gilead Sciences received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Yeytuo, the commercial name for Lenacapavir.

The medication offers adults and adolescents a twice-yearly injection designed to reduce their risk of contracting HIV-1, marking a departure from traditional daily pill regimens.

Health Cabinet Secretary Hon. Aden Duale, EGH, emphasized that the recommendation follows a thorough scientific assessment of Lenacapavir’s quality, safety, and efficacy.

The evaluation was conducted according to Kenyan law and applicable international regulatory standards, ensuring the medication meets the highest benchmarks for public health interventions.

Kenya stands among the first African countries to recommend Lenacapavir for registration, demonstrating the nation’s commitment to innovative healthcare solutions.

This decision aligns with recent guidance from the World Health Organization and showcases Kenya’s growing regulatory capacity and leadership in facilitating timely access to cutting-edge health technologies that address public health priorities.

The medication works by targeting critical stages of the human immunodeficiency virus lifecycle, effectively preventing HIV infection before it can establish itself in the body.

The long-acting formulation requires administration only twice per year, providing a practical alternative for people who struggle with daily oral HIV prevention medicines.

Kenya has already made substantial progress in expanding access to daily oral PrEP across all 47 counties.

Despite these achievements, many individuals face difficulties maintaining long-term daily pill use due to various obstacles including pill fatigue, stigma associated with daily medication, and challenges with consistent adherence to treatment schedules.

Long-acting injectable prevention options like Lenacapavir address these barriers by dramatically reducing the frequency of medication administration.

This approach broadens access to effective HIV prevention methods and offers greater flexibility for populations who need it most.

The country has been identified as a priority location for the initial rollout of Lenacapavir through global partnerships.

Preparatory planning is currently underway to ensure the medicine reaches populations at substantial risk of HIV infection in a timely, equitable, and responsible manner.

The Ministry of Health continues to demonstrate its commitment to expanding HIV prevention options and reducing new HIV infections across the nation.

These efforts support the national goal of ending HIV as a public health threat while maintaining rigorous standards to ensure that all health products introduced in Kenya meet international benchmarks for safety, quality, and effectiveness.